Abstract
A newly developed somatostatin radioligand, DOTA-[D-Phe1-Tyr3]-octreotide (DOTATOC), has been synthesised for therapeutic purposes, because of its stable and easy labelling with yttrium-90. The aim of this study was to determine the dosage, safety profile and therapeutic efficacy of 90Y-DOTATOC in patients with cancers expressing somatostatin receptors. We recruited 30 patients with histologically confirmed cancer. The main inclusion criterion was the presence of somatostatin receptors as documented by 111In-DOTATOC scintigraphy. 90Y-DOTATOC was injected intravenously using a horizontal protocol: patients received equivalent-activity doses in each of three cycles over 6 months. The first six patients received 1.11 GBq per cycle and the four successive groups of six patients received doses increasing in 0.37-GBq steps. Toxicity was evaluated according to WHO criteria. No patient had acute or delayed adverse reactions up to 2.59 GBq 90Y-DOTATOC per cycle (total 7.77 GBq). After a total dose of 3.33 GBq, one patient developed grade II renal toxicity 6 months later. The maximum tolerated dose per cycle has not yet been reached, although transient lymphocytopenia has been observed. Total injectable activity is limited by the fact that the maximum dose tolerated by the kidneys has been estimated at 20-25 Gy. Complete or partial tumour mass reduction occurred in 23% of patients; 64% had stable and 13% progressive disease. It is concluded that high activities of 90Y-DOTATOC can be administered with a low risk of myelotoxicity, although the cumulative radiation dose to the kidneys is a limiting factor and requires careful evaluation. Objective therapeutic responses have been observed.
| Original language | English |
|---|---|
| Pages (from-to) | 426-434 |
| Number of pages | 9 |
| Journal | European Journal Of Nuclear Medicine |
| Volume | 28 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2001 |
Fingerprint
Keywords
- Y/In-DOTATOC
- Peptides
- Receptor-mediated radiotherapy
- Somatostatin analogue
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. / Paganelli, Giovanni; Zoboli, Stefania; Cremonesi, Marta; Bodei, Lisa; Ferrari, Mahila; Grana, Chiara; Bartolomei, Mirco; Orsi, Franco; De Cicco, Concetta; Mäcke, Helmut R.; Chinol, Marco; De Braud, Filippo.
In: European Journal Of Nuclear Medicine, Vol. 28, No. 4, 2001, p. 426-434.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide
AU - Paganelli, Giovanni
AU - Zoboli, Stefania
AU - Cremonesi, Marta
AU - Bodei, Lisa
AU - Ferrari, Mahila
AU - Grana, Chiara
AU - Bartolomei, Mirco
AU - Orsi, Franco
AU - De Cicco, Concetta
AU - Mäcke, Helmut R.
AU - Chinol, Marco
AU - De Braud, Filippo
PY - 2001
Y1 - 2001
N2 - A newly developed somatostatin radioligand, DOTA-[D-Phe1-Tyr3]-octreotide (DOTATOC), has been synthesised for therapeutic purposes, because of its stable and easy labelling with yttrium-90. The aim of this study was to determine the dosage, safety profile and therapeutic efficacy of 90Y-DOTATOC in patients with cancers expressing somatostatin receptors. We recruited 30 patients with histologically confirmed cancer. The main inclusion criterion was the presence of somatostatin receptors as documented by 111In-DOTATOC scintigraphy. 90Y-DOTATOC was injected intravenously using a horizontal protocol: patients received equivalent-activity doses in each of three cycles over 6 months. The first six patients received 1.11 GBq per cycle and the four successive groups of six patients received doses increasing in 0.37-GBq steps. Toxicity was evaluated according to WHO criteria. No patient had acute or delayed adverse reactions up to 2.59 GBq 90Y-DOTATOC per cycle (total 7.77 GBq). After a total dose of 3.33 GBq, one patient developed grade II renal toxicity 6 months later. The maximum tolerated dose per cycle has not yet been reached, although transient lymphocytopenia has been observed. Total injectable activity is limited by the fact that the maximum dose tolerated by the kidneys has been estimated at 20-25 Gy. Complete or partial tumour mass reduction occurred in 23% of patients; 64% had stable and 13% progressive disease. It is concluded that high activities of 90Y-DOTATOC can be administered with a low risk of myelotoxicity, although the cumulative radiation dose to the kidneys is a limiting factor and requires careful evaluation. Objective therapeutic responses have been observed.
AB - A newly developed somatostatin radioligand, DOTA-[D-Phe1-Tyr3]-octreotide (DOTATOC), has been synthesised for therapeutic purposes, because of its stable and easy labelling with yttrium-90. The aim of this study was to determine the dosage, safety profile and therapeutic efficacy of 90Y-DOTATOC in patients with cancers expressing somatostatin receptors. We recruited 30 patients with histologically confirmed cancer. The main inclusion criterion was the presence of somatostatin receptors as documented by 111In-DOTATOC scintigraphy. 90Y-DOTATOC was injected intravenously using a horizontal protocol: patients received equivalent-activity doses in each of three cycles over 6 months. The first six patients received 1.11 GBq per cycle and the four successive groups of six patients received doses increasing in 0.37-GBq steps. Toxicity was evaluated according to WHO criteria. No patient had acute or delayed adverse reactions up to 2.59 GBq 90Y-DOTATOC per cycle (total 7.77 GBq). After a total dose of 3.33 GBq, one patient developed grade II renal toxicity 6 months later. The maximum tolerated dose per cycle has not yet been reached, although transient lymphocytopenia has been observed. Total injectable activity is limited by the fact that the maximum dose tolerated by the kidneys has been estimated at 20-25 Gy. Complete or partial tumour mass reduction occurred in 23% of patients; 64% had stable and 13% progressive disease. It is concluded that high activities of 90Y-DOTATOC can be administered with a low risk of myelotoxicity, although the cumulative radiation dose to the kidneys is a limiting factor and requires careful evaluation. Objective therapeutic responses have been observed.
KW - Y/In-DOTATOC
KW - Peptides
KW - Receptor-mediated radiotherapy
KW - Somatostatin analogue
UR - http://www.scopus.com/inward/record.url?scp=0035094321&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035094321&partnerID=8YFLogxK
U2 - 10.1007/s002590100490
DO - 10.1007/s002590100490
M3 - Article
C2 - 11357492
AN - SCOPUS:0035094321
VL - 28
SP - 426
EP - 434
JO - European Journal of Pediatrics
JF - European Journal of Pediatrics
SN - 0340-6199
IS - 4
ER -